Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

March 6, 2020 / Arfinn Med MD /

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Aching for a Better Alternative?

To close out Arthritis Awareness Month, we’re highlighting how medical marijuana may be a beneficial alternative treatment for this painful and debilitating disease. With over 31 million Americans suffering from various types of arthritis, the condition stands as the leading disability throughout the U.S. As many may know, arthritis is most common among the middle-aged…
Read More →

Assessing Health-Related Outcomes of Medical Cannabis Use among Older Persons: Findings from Colorado and Illinois

ABSTRACT Objectives To assess health-related outcomes associated with medical cannabis use among older patients in Colorado and Illinois enrolled in their home state’s medical cannabis program. Methods Cross-sectional data from anonymous surveys were collected from 139 persons over the age of 60 using medical cannabis in the past year. We used structural equation modeling (SEM)…
Read More →

Study on cannabis chemical as a treatment for pancreatic cancer may have ‘major impact,’ Harvard researcher says

Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second leading cause of cancer-related death by 2020. Headlines about the illness, as a result, tend to be discouraging. But this month scientists from Harvard University’s Dana-Farber…
Read More →

Medical marijuana: Florida House seeks to intervene in ‘monumental’ case

TALLAHASSEE — Florida House leaders should be able to participate in a lawsuit that could revolutionize the state’s medical marijuana market, a lawyer for the Republican-led chamber told a three-judge panel of the 1st District Court of Appeal Tuesday. But Tampa-based Florigrown argued that legislators instead should concentrate on fixing the law, aimed at carrying…
Read More →

Doctors and patients are flying blind as medical marijuana use rises, research lags

Marijuana’s role in the health care universe has grown exponentially over the past few years. Currently, 33 U.S. states have legalized the use of medical marijuana, and more and more states are considering making it legal for recreational purposes as well. As cannabis becomes more accessible, many people are turning to tetrahydrocannabinol (THC) and cannabidiol (CBD) products to…
Read More →

More Treatment Options, Better Patient Outcomes

As more states start to pass medical marijuana legislation, patients benefit from having more options available to them regarding their treatment.  In fact, a recent study from Columbia University’s Irving Medical Center found that, “States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana…
Read More →

Leave a Comment

You must be logged in to post a comment.